Technical Articles

In-depth analysis of how interleukin-2 commands the T-cell army and its central role in cancer treatment, autoimmune diseases, and infections.

Obtaining large numbers of highly active human peripheral blood-derived T cells is a critically important technical step in immunotherapy development, oncology research, and the exploration of immune response mechanisms. Traditional T cell expansion requires researchers to independently optimize the concentrations of anti-CD3 and anti-CD28 antibodies, as well as the ratio of IL-2 - a process that is cumbersome and involves variables that are difficult to control.

Cytokine-induced killer (CIK) cells demonstrate broad application prospects in adoptive immunotherapy for tumors. As a highly efficient, non-MHC-restricted killer cell population, CIK cells can effectively recognize and eliminate various tumor cells with minimal side effects.

Th2 cells, as a crucial subset of CD4+ helper T cells, undergo a precisely regulated differentiation process. Naïve CD4+ T cells recognize the MHC class II-peptide complex on the surface of antigen-presenting cells through their T cell receptor, receiving the first signal; simultaneously, they obtain the second signal through costimulatory molecules such as CD28, thereby completing the dual-signal activation.

IL-2 (interleukin-2) is a pleiotropic cytokine, originally known as "T cell growth factor", mainly secreted by CD4 ⁺ T cells after activation by T cell receptor (TCR) and CD28 co stimulation.

In the fields of immunology and disease treatment, thymic stromal lymphopoietin (TSLP) is emerging as a rising star. As a pleiotropic cytokine belonging to the short-chain four-α-helix bundle type I IL-2 family, TSLP not only plays a key role in allergic and autoimmune diseases but also demonstrates unique regulatory functions in complex conditions such as cancer and metabolic syndrome.

Interleukin-2 (IL-2) is a pleiotropic cytokine that has received significant attention for its dual role in immune regulation since its discovery in 1976. As a key regulatory factor for T cell proliferation, IL-2 can exert anti-tumor effects by activating effector T cells (Teff) and natural killer (NK) cells, as well as inhibiting immune responses by stimulating regulatory T cells (Treg).